Immunex/Hoechst CSF research agreement
Executive Summary
Immunex expanding research agreement with the Hoechst subsidiary, Behringwerke, to include additional colony stimulating factors (CSFs). Immunex began work with Behringwerke in mid-1984 and has one CSF protein (GM-CSF) headed for clinical trials "in early 1986." The colony stimulating factors covered by the new agreement "include granulocyte CSF, macrophage CSF, Hemopoietin-1, and Burst Promoting Activity".